EGFR and non-small cell lung carcinoma: According to previous research, through the Wnt/-catenin signaling pathway, PMMB-317 stopped A549 cells from migrating with dose-dependence, blocked G2/M cell cycle, induced apoptosis, and inhibit the activity of EGFR [30], which were consistent with our speculation that the effects of Afatinib on NSCLC cells can be mediated by inhibition of EGFR receptor activity.